Associated Papers
Antiviral drug recognition and elevator-type transport motions of CNT3.
Wright NJ et al.
Nature Chemical Biology, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
38802404 (PubMed )
Supplement: 41397_2024_338_MOESM2_ESM.xlsx › Sheet1
Cryo-EM structure of the human concentrative nucleoside transporter CNT3.
Zhou Y et al.
Plos Biology, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
30206299 (PubMed )
Supplement: 41397_2018_44_MOESM5_ESM.xlsx › Sheet1
Identification and Characterization of a Secondary Sodium-Binding Site and the Main Selectivity Determinants in the Human Concentrative Nucleoside Transporter 3.
Arimany-Nardi C et al.
Molecular Pharmaceutics, 2017
Functional analysis of the human concentrative nucleoside transporter-1 variant hCNT1S546P provides insight into the sodium-binding pocket.
Cano-Soldado P et al.
American Journal of Physiology. Cell Physiology, 2012
The human concentrative nucleoside transporter-3 C602R variant shows impaired sorting to lipid rafts and altered specificity for nucleoside-derived drugs.
Errasti-Murugarren E et al.
Molecular Pharmacology, 2010
A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum.
Errasti-Murugarren E et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2009
Functional characterization of a nucleoside-derived drug transporter variant (hCNT3C602R) showing altered sodium-binding capacity.
Errasti-Murugarren E et al.
Molecular Pharmacology, 2008
Select a paper to view details